Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endomet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Aghajanian, Carol, Sill, Michael W., Darcy, Kathleen M., Greer, Benjamin, McMeekin, D. Scott, Rose, Peter G., Rotmensch, Jacob, Barnes, Mack N., Hanjani, Parviz, Leslie, Kimberly K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107744/
https://ncbi.nlm.nih.gov/pubmed/21537039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.6397
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados